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Interference of the T Cell and Antigen-Presenting Cell
Costimulatory Pathway Using CTLA4-Ig (Abatacept)
Prevents Staphylococcal Enterotoxin B Pathology
Sarah J. C. Whitfield,* Chris Taylor,* Jane E. Risdall,*,† Gareth D. Griffiths,*
James T. A. Jones,* E. Diane Williamson,* Sjoerd Rijpkema,‡ Luisa Saraiva,x
Sandrine Vessillier,x A. Christopher Green,* and Alun J. Carter*,{
Staphylococcal enterotoxin B (SEB) is a bacterial superantigen that binds the receptors in the APC/T cell synapse and causes in-
creased proliferation of T cells and a cytokine storm syndrome in vivo. Exposure to the toxin can be lethal and cause significant
pathology in humans. The lack of effective therapies for SEB exposure remains an area of concern, particularly in scenarios of acute
mass casualties. We hypothesized that blockade of the T cell costimulatory signal by the CTLA4-Ig synthetic protein (abatacept)
could prevent SEB-dependent pathology. In this article, we demonstrate mice treated with a single dose of abatacept 8 h post SEB
exposure had reduced pathology compared with control SEB-exposed mice. SEB-exposed mice showed significant reductions in
body weight between days 4 and 9, whereas mice exposed to SEB and also treated with abatacept showed no weight loss for
the duration of the study, suggesting therapeutic mitigation of SEB-induced morbidity. Histopathology and magnetic resonance
imaging demonstrated that SEB mediated lung damage and edema, which were absent after treatment with abatacept. Analysis
of plasma and lung tissues from SEB-exposed mice treated with abatacept demonstrated significantly lower levels of IL-6 and IFN-g
(p < 0.0001), which is likely to have resulted in less pathology. In addition, exposure of human and mouse PBMCs to SEB in vitro
showed a significant reduction in levels of IL-2 (p < 0.0001) after treatment with abatacept, indicating that T cell proliferation is
the main target for intervention. Our findings demonstrate that abatacept is a robust and potentially credible drug to prevent toxic
effects from SEB exposure. The Journal of Immunology, 2017, 198: 3989–3998.
S
taphylococcus aureus is known to produce at least 15 se-
rologically distinct superantigens, including staphylococ-
cal enterotoxin B (SEB) (1, 2). SEB is the superantigen
commonly associated with staphylococcal food poisoning, but it
can also cause widespread systemic damage and toxic shock
syndrome (3, 4). The toxin has been shown to cause lethal pul-
monary disease and contribute to pneumonia in vivo (5–7). SEB is
stable to aerosolization, and inhalation of small amounts can cause
severe lung pathology, shock, and death (4–7).
Aerosolized SEB exposure in nonhuman primates has an esti-
mated LD50 of 21.7–44.1 mg/kg; however, no direct data are
available for this in humans (2). The relative ease with which stable
aerosols of SEB can be produced has resulted in this superantigen
featuring on both the U.K. and U.S. biological warfare threat lists
(2). Thus, weaponized SEB used in either a bioterrorist or military
context can result in a mass casualty scenario (2).
Recent research has looked into the development of effective
treatments for SEB exposure and intoxication, including agent-specific
medical countermeasures (e.g., antitoxins) and wider-spectrum ther-
apies (e.g., anti-inflammatory agents) to target the resulting immu-
nopathology (8). The development of broad-spectrum therapeutic
agents, that is, those that are effective against superantigens in gen-
eral, is of particular interest.
Several challenges in regard to these therapeutic agents remain.
Ideally, an effective treatment for superantigen exposure should only
require a single dose to minimize the logistic constraints in a mass
casualty situation and facilitate management of milder forms of the
disease, such as food poisoning (9, 10). Treatment of superantigen
exposure will need to occur within a manageable postexposure window,
allowing the time for detection and diagnosis required for effective
treatment. Thus, interventions that offer a broad spectrum of activity
against multiple superantigens and are effective when administered as a
postexposure treatment are credible therapeutic candidates (11).
Staphylococcal enterotoxins are extremely potent activators of
T cells (12, 13). These toxins bind directly to the MHC class II
molecules on APCs and the variable b-chains of the TCR, and
activate the endogenous pathways dependent upon immune
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synapse formation (12, 13). CD28, a costimulatory receptor on
T cells, has been recently identified as a superantigen receptor
(14). Concerted interaction of the superantigen with all three re-
ceptors (CD28, MHC class II, and TCR) allows stable synapse
formation resulting in exceptionally robust T cell responses, par-
ticularly Th1 cytokine induction, and lethality (14). Via this
mechanism, SEB activates ∼20% of the T cell population,
whereas exposure to normal Ags activates ,0.01% of T cells (14,
15). CTLA4 plays an important role in controlling excessive T cell
activation (16). This receptor specifically binds the B7 receptors
(CD80/CD86) on APCs and acts as a negative costimulatory re-
ceptor by preventing CD28 interaction with B7 receptors (16). The
inhibitory effect of native CTLA4 is through the active removal of
the B7 receptor from the surface of APC (16). The resultant removal
of the B7 receptor prevents interaction with CD28. Furthermore,
expression of CTLA4 has been shown to set T cell activation
thresholds through intracellular tyrosine phosphatase regulation (17).
A synthetic version of CTLA4 comprising a fusion protein with the
Fc region of the human Ig (IgG1) and the extracellular domain of the
receptor, termed abatacept (CTLA4-Ig), has been developed to
mitigate T cell activation in reactive arthritis (18, 19).
We hypothesized that a single dose of abatacept, given post
exposure, could mitigate T cell and APC activation through im-
mune synapse formation, and thereby reduce the pathology induced
by SEB in mice and in human PBMCs.
Materials and Methods
Toxin and therapeutics
SEB toxin (1 endotoxin unit/50 mg) was obtained from Public Health
England (Porton Down, Wiltshire, U.K.). Abatacept was obtained from
Bristol-Myers Squibb (Uxbridge, Middlesex, U.K.). Ipilimumab (Yervoy)
was obtained from Idis (Weybridge, U.K.). Con A and LPS were from
Sigma-Aldrich (Poole, Dorset, U.K.). All reagents were initially prepared
in PBS (Life Technologies, Paisley, U.K.) with working dilutions in sterile
RPMI 1640 media containing 15% (v/v) FCS (Sigma-Aldrich), 100 U/ml
penicillin, 0.1 mg/ml streptomycin solution (Sigma-Aldrich), and 2 mM
L-glutamine (Sigma-Aldrich).
Splenocyte preparation
Fifteen male BALB/C mice (6–7 wk old; Charles River Laboratories,
Margate, Kent, U.K.) were killed by cervical dislocation, and their spleens
were removed aseptically. For each experiment spleens from three mice
were passed through a 10-mm cell strainer. Each strained spleen prepara-
tion was resuspended in 30 ml of RPMI 1640 medium, supplemented as
described earlier. Each spleen cell suspension was centrifuged for 10 min
at 350 3 g, and the cell pellet was lysed with 3 ml of RBC lysing buffer
(Sigma-Aldrich) for 1 min. Splenocytes were washed and resuspended in
RPMI 1640 medium. Cell counts were determined using a Neubauer he-
mocytometer and adjusted with supplemented RPMI 1640 medium to give
a final live cell count of 2.0 3 107 cells/ml.
Cell proliferation (MTT) assay
The ability of abatacept to inhibit the proliferative effect of SEB was
measured using a modified cell proliferation technique (20). Splenocytes
were seeded into 96-well flat-bottom Corning Costar cell culture plates
(Sigma-Aldrich) at a cell density of 13 106 cells per well. To the wells we
added 100 ml of PBS (negative control), 0.5 mg SEB/ml (positive control),
or a mixture of 0.5 mg SEB/ml and abatacept (2-fold dilution ranging from
0.3 to 10 mg/ml); Con A was included as a positive control.
After 48 h, cell proliferation was measured using an MTT assay with
minor modifications from the manufacturer’s instructions (Promega,
Madison, WI). Cell proliferation was determined by measuring absorbance
at 570 nm (A570) using a plate reader (Thermo Fisher Scientific, Basingstoke,
U.K.), and the result was normalized to the negative control (0% baseline)
and the positive control (100% SEB).
Cell cytotoxicity assay
A baseline cytotoxicity assay was conducted on a 48-h culture of murine
splenocytes cultured to establish the relative toxicities of SEB and abatacept,
individually and in combination. Splenocytes were seeded into 96-well
flat-bottom cell culture plates (B. E. Thompson Supplies, Andover, U.K.)
at a cell density of 5 3 104 cells per well and incubated under the fol-
lowing conditions: 1) splenocytes in RPMI 1640 alone; 2) splenocytes in
RPMI 1640 with abatacept; 3) splenocytes in RPMI 1640 with 0.5 mg
SEB/ml; and 4) splenocytes in RPMI 1640 supplemented with SEB 0.5
mg/ml and abatacept at 0.625 to 10 mg/ml.
After 48 h, cell death was determined using a Promega Multi-Fluor
cytotoxicity assay (Promega), in accordance with the manufacturer’s in-
structions. Dead cell numbers were determined by fluorescence at 485Ex/
535Em 3 h after the addition of 53 Multi-Fluor reagent. Results were
expressed as mean fluorescence intensity and SEM for each group.
SEB stimulation of human cells in vitro
Human whole blood was donated by consenting employees of National
Institute for Biological Standards and Control (NIBSC; Potters Bar, U.K.).
PBMCs were isolated from heparinized whole blood (10 IU/ml; Wockhardt,
Wrexham, U.K.) by density gradient centrifugation using Lymphoprep (Axis-
Shield Diagnostics, Dundee, U.K.) layered beneath whole blood diluted 1:2
with PBS. PBMCs were resuspended at 1 3 106/ml in complete RPMI 1640
(RPMI 1640, 10% FCS, L-glutamine, penicillin, and streptomycin) and
200 ml of cells was seeded per well in 96-well cell culture cluster plates
(Corning, New York, NY). SEB (10 ng/ml), abatacept (1 and 10 mg/ml),
and ipilimumab (1 and 10 mg/ml) were added to the wells.
For measurement of cytokine release by ELISA, cells were incubated at
37˚C under 5% CO2 for 24 h. Each condition was tested in triplicate. The
cells were centrifuged, and the supernatants were collected and stored at
220˚C until analysis.
Where intracellular cytokine staining was measured, 10 mg of brefeldin
A/ml (secretion inhibitor) was added to the cell cultures after 1-h stimu-
lation with the different treatments to block the secretion of cytokines (21).
Cells were incubated at 37˚C under 5% CO2 overnight. Each condition was
tested in triplicate. Cytokine responses to therapeutic mAbs were assessed
after overnight incubation using intracellular staining and FACS analysis.
Human cytokine responses to in vitro treatments
Concentrations of TNF-a, IL-2, and IFN-g in culture supernatants were
measured by ELISA. In brief, Nunc MaxiSorp plates (Thermo Fisher
Scientific) were coated overnight at 4˚C with respective capture Abs (anti–
TNF-a capture Ab mAb clone 357-101-4), anti–IL-2 capture Ab (R&D
MAB602; R&D Systems, U.K.), or anti–IFN-g capture Ab (BD 551221;
BD Biosciences, Oxford, U.K.). Plates were blocked with 1% BSA; then
50 ml of the culture supernatant or the relevant WHO International Stan-
dards (Second WHO Internal Standard for TNF-a NIBSC 88/786, IL-2
standard NIBSC 86/564, IFN-g standard NIBSC 88/606) was added to
the plates together with 50 ml of biotinylated anti–TNF-a (clone H91;
NIBSC), or biotinylated anti–IL-2 (R&D BAF202) or biotinylated anti–
IFN-g (BD 554550; BD Biosciences). Plates were incubated overnight at
4˚C and developed using streptavidin-HRP conjugate (Jackson) diluted
1/30,000 and o-phenylenediamine dihydrochloride substrate (Sigma-
Aldrich). The reaction was then stopped with 1M H2SO4, and colorimetric
measurements were performed at 490 nm using SpectraMax plate reader
(Molecular Devices).
Polychromatic intracellular cytokine staining was performed using the
manufacturer-recommended amounts of the following anti-human fluoro-
chrome conjugates for surface staining for 30 min at 4˚C: CD3-FITC (clone
UCHT1; BioLegend, San Diego, CA), CD4-allophycocyanin-Cy7 (clone
RPA-T4; BioLegend), and CD8-PerCP-Cy5.5 (clone RPA-T8; BioLegend).
After surface staining, cells were washed, fixed, and permeabilized using
Fix&Perm Cell Permeabilization Kit (GAS004; Thermo Fisher Scientific). For
intracellular cytokine staining, combinations of the following anticytokine
fluorochrome conjugates were used at the manufacturer-recommended
amounts for 30 min at 4˚C: TNF-a–PE (clone Mab11; BD Biosciences),
IL-2–allophycocyanin (clone MQ1-17H12; BioLegend), and IFN-g Pacific
blue (clone 4S.B3; BioLegend). The cells were washed and resuspended in
PBS 0.5–1% FCS for analysis. Acquisition of 10,000 gated PBMC events per
well was performed using a FACSCanto II flow cytometer equipped with a
high-throughput screening plate reader (BD Biosciences) and analyzed using
FlowJo v10 software. Percentage of PBMCs positive for the different cyto-
kines was quantified.
In vitro expression of IL-1b, IL-2, and CCL2 in murine
splenocytes
Murine splenocytes were cultured in RPMI 1640 with PBS (negative control),
0.5 mg SEB/ml (positive control), 3.1 mg Con A/ml (proliferation control),
5 mg LPS/ml (positive control), and 0.5 mg SEB/ml plus abatacept at 0.3 to
10 mg/ml for 48 h in a final volume of 1 ml/well. Supernatants were prepared
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by centrifugation of cultures at 1000 3 g for 10 min at room temperature.
Quantitative ELISAs for IL-1b, IL-2, and CCL2 were performed according to
manufacturer’s instructions (Quantikine; R&D Systems, Minneapolis, MN).
Supernatants recovered from splenocytes exposed to SEB and treated with
abatacept were compared with supernatants from the negative control and
positive controls (cells exposed to either SEB, Con A, or LPS).
Animal husbandry
Age-matched male BALB/c mice (6–7 wk old; Charles River Laboratories)
were used in all in vivo studies. On receipt, animals acclimatized to the
facility before being studied. All investigations involving animals con-
formed to the Animal (Scientific Procedures) Act 1986 and were carried
out according to the Home Office Project License, adhering to the clearly
defined humane end points of no .30% weight loss and reduced mobility
in the presence of severe clinical signs of intoxication, which include
piloerection, limping, hunched posture, and dull or sluggish movement.
Mice were housed in rooms maintained at 21 6 2˚C on a 12/12 h
dawn/dusk cycle. Humidity was maintained at 55 6 10% with air flow of
15–18 changes/h, and mice were given food and water ab libitum. Mice were
fed a standard pelleted Teklad 19% protein irradiated diet (Harlan Teklad,
Bicester, U.K.).
Development of an in vivo model for intranasal exposure to
SEB
A murine model for intranasal (i.n.) exposure to SEB was developed. The
model eschewed the use of adjuncts such as LPS, normally used to sensitize
the mice, because these agents may cause systemic inflammation and liver
damage (22). Mice (six per group) were randomly assigned to control or
treatment groups and were weighed on day 0. Intranasal instillation of SEB
or PBS was performed under light anesthesia (halothane 5% in oxygen) with
recovery. Either SEB was prepared in 50 ml of sterile PBS (Life Technol-
ogies) or the total dose was divided between the two nares. Control animals
received 50 ml of PBS divided between the two nares. After exposure, the
mice were returned to their home cages and allowed to recover, then sub-
sequently received 100 ml of i.v. PBS at 3 or 8 h post i.n. administration of
SEB. All animals were assessed daily for 14 d or until they met the criteria
for humane cull. To determine the optimal sublethal i.n. dose of SEB, we
exposed mice to SEB 0.5 and 0.25 mg/g body weight (Supplemental Fig. 2).
Abatacept in vivo efficacy study: 3 and 8 h post exposure
In subsequent studies, mice were exposed i.n. to SEB at 0.25 mg/g body
weight and abatacept given i.v. at 10 mg/g body weight. The efficacy of
abatacept was determined at 3 h post exposure: mice received an i.n.
administration of SEB or PBS followed by an i.v. injection of either
abatacept or PBS.
The efficacy of abatacept against SEB was also determined at 8 h post
exposure. In this case mice were divided in three groups: group 1, i.n. PBS
followed 8 h later by i.v. PBS; group 2, i.n. SEB followed 8 h later by i.v. PBS;
and group 3, i.n. SEB followed 8 h later by i.v. abatacept. Each group consisted
of six mice, which were monitored for 14 d post i.v. administration.
In addition, three experimental replicates were performed to study the
efficacy of abatacept against SEB at 8 h post exposure with a final total of 42
mice per group (two experimental replicates of 18 mice and one experi-
mental replicate of 6 mice for magnetic resonance imaging [MRI]). On days
3, 6, and 14 post SEB exposure, a total of six mice from each group were
culled and analyzed for histopathology, gross pathology, and cytokine
analysis. At days 3 and 6, three mice from each group were also culled for
MRI analysis of lung edema. Mice were weighed and observed for signs of
distress daily.
Behavioral observations and signs of intoxication
Mice were assessed daily for 14 d post SEB exposure for changes in body
weight and signs of SEB intoxication. The appearance of each mouse was
noted and graded according to severity guidelines and the requirements of
the Home Office license. For piloerection, mice were scored 0–3, with
0 representing a normal mouse and 3 representing a mouse showing severe
piloerection. For abdominal pinching, a code of mild, medium, or severe
was recorded in each case. This study was repeated on three occasions to
ensure robust data were collected.
Gross pathology and histopathology
Eighteen mice were treated to study the efficacy of abatacept given 8 h post
exposure. On days 3, 6, and 14, six mice were culled and tissues taken for
gross pathology. Lungs, liver, and spleen were visually scored 0–4
according to in-house guidelines ranging from normal (0), mild (1),
moderate (2), substantial (3), to severe tissue damage (4), and their weights
as a percentage of the animal’s body weight were calculated.
Lung tissue from each animal was snap frozen in liquid N2, cryosec-
tioned at 5 mm after a postmortem examination, and stained with H&E.
Sections were examined using a Zeiss Axioplan MRc5 microscope
(Zeiss, Oberkochen, Germany) and camera using the 103 (0.30) objective
to determine tissue damage seen from SEB intoxication. Severity of lung
inflammatory cell infiltrate and necrosis was assessed and scored 0–4 as
percentage area of tissue damage: 0% (0),,25% (1), 26–50% (2), 51–75%
(3), or 76–100% (4).
Cytokine and chemokine analysis
On days 3, 6, and 14, whole blood in EDTA was taken from six mice in
the 8-h postexposure treatment experiment for cytokine analysis. Blood
samples were rolled for 5 min at room temperature before being centrifuged
at 1000 3 g for 15 min at 4˚C. Plasma supernatant was subsequently re-
moved, frozen, and stored before analysis using a Bio-Rad Bio-Plex an-
alyzer 200 (Bio-Rad, Hercules, CA). Samples were diluted 1:4, according
to manufacturer’s instructions, before analysis with Luminex performance
assay for murine CCL2, GM-CSF, IFN-g, IL-1b, IL-2, IL-4, IL-5, IL-6,
IL10, IL-12p70, IL-17A, CXCL1, CXCL2, TNF-a, and VEGF (R&D
Systems).
Magnetic resonance imaging
Three mice from each group were killed on days 3 and 6 for immediate
postmortem MRI. Mice were imaged within 10 min of sacrifice to mitigate
postmortem changes. All MRI was performed at 9.4 T using a Bruker AVIII
microimaging system operating at 400.16 MHz for 1H and Bruker ParaVision5.1
for data acquisition (Bruker, Coventry, U.K.). A transmit/receive 1H Quad
40-mm birdcage resonator was used in all experiments. Data were acquired
using the microimaging Bruker FLASH method using a gradient echo and
an echo time of 2.075 ms. A total of 16 averages were acquired with a slice
thickness of 0.5 mm, a 30˚ flip angle, and a repetition time of 1 s.
All images were acquired as a 2563 256 matrix resulting in a scan time of
∼1 h 8 min. Images were processed using OriginPro 9.1 software.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 6. Normality of
values was determined using a Kolmogorov–Smirnov normality test and,
where appropriate, the data were log transformed to normality. For the
proliferation, in vitro mouse cytokine and cytotoxicity assays matched
analysis was performed using a one-way ANOVAwith a Dunnett posttest.
A linear mixed model was developed to compare the weight changes in the
in vivo studies. Survival analysis was performed using Kaplan–Meier
survival curves; statistical comparisons were made with log-rank (Mantel–
Cox) test. For cytometric bead array cytokine analysis, five-parameter
logistic curves were used to fit standard curves. Lung visual pathology
scores, lung inflammatory cell infiltrate, lung body to organ weight, and
plasma cytokine/chemokine levels were compared using a Kruskal–Wallis
with a Dunn posttest comparing the SEB-control with the PBS-control and
abatacept treatment group. Cytokine/chemokine levels in the lungs were
analyzed using a one-way ANOVA with Dunnett posttest. For human
in vitro assays, statistical analysis was performed using two-way repeated-
measures ANOVA with Dunnett posttest.
Results
Abatacept reduces SEB-induced proliferation and
proinflammatory cytokine and chemokine production of murine
splenocytes in vitro
SEB is known to induce T cell proliferation and proinflammatory
cytokine production (8). In the MTTassay, treatment of cells exposed
to SEB with abatacept resulted in a significant dose-dependent re-
duction in proliferation by 40% at 0.3 mg abatacept/ml and by 60% at
10 mg abatacept/ml (p = 0.0002; Fig. 1A). No significant cytotoxicity
was observed after treatment of splenocytes with 10 mg abatacept/ml
either alone or in combination with SEB 0.5 mg/ml (Supplemental
Fig. 1). The production of IL-1b, IL-2, and CCL2 of cells exposed to
SEB increased significantly when compared with PBS (all cytokine
levels were p , 0.05; see Fig. 1B–D). Treatment of SEB-stimulated
splenocytes with abatacept significantly reduced levels of IL-1b (p,
0.01; Fig. 1B), IL-2 (p , 0.001; Fig. 1C), and CCL2 (p , 0.05; Fig.
1D) compared with untreated controls.
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Abatacept therapy after i.n. administration of SEB after 3 and
8 h prevents weight loss and reduces clinical signs of morbidity
To assess the efficacy of abatacept to prevent SEB-induced pathology,
we used an i.n. murine model of SEB intoxication. Mice were given
either SEB 0.5 or 0.25 mg/g body weight via i.n. instillation followed
by subsequent i.v. administration of PBS. At a dose of SEB 0.5 mg/g,
two of six of mice survived, whereas SEB 0.25 mg/g resulted in four
of six mice surviving (Fig. 2A). Significant differences in survival
were observed between the control PBS group and mice receiving
SEB 0.5 mg/g (p = 0.0004) or 0.25 mg/g (p = 0.0188). Therefore, a
dose of SEB 0.25 mg/g body weight was subsequently used to
evaluate the efficacy of abatacept. Loss in body weight of SEB-
exposed mice was most severe at day 5, with a reduction in mean
body weight of 25.5% (95% confidence interval [CI]6 5.0%; Fig. 2C).
The mitigating effect on SEB was determined 3 and 8 h post
exposure (Fig. 2B, 2C). Mice, treated with SEB or PBS i.n., re-
ceived abatacept or PBS via i.v. injection. Mice were weighed and
scored for clinical signs daily until day 14 (Fig. 2D–F).
Mice exposed to SEB showed a significant reduction (as de-
termined by mixed linear modeling and 95% CI) in body weight
between days 4 and 9 (Fig. 2B, 2C). Treatment with abatacept at 3
or 8 h prevented weight loss in SEB-exposed mice at these time
points (Fig. 2B, 2C).
Behavioral observations and intoxication scoring supported the
observed changes in weight. By day 3, 50% of the SEB-exposed
mice showed signs of hunching and piloerection, with recovery
by day 10 (Fig. 2E). By contrast, mice exposed to SEB and treated
with abatacept showed few signs of intoxication (Fig. 2F) and
appeared similar to the PBS-control group (Fig. 2D).
SEB-induced lung pathology is prevented after abatacept
therapy
To determine the efficacy of abatacept to prevent SEB lung pa-
thology, we analyzed lung tissue from mice exposed to SEB, PBS,
and a mixture of SEB and abatacept for edema and tissue damage.
At days 3, 6, and 14, mice were sacrificed and lung-to-body weight
ratio, inflammatory cell infiltrate by histology, and visual evalu-
ation of lung necropsy were determined. Mice treated with PBS
showed no signs of tissue damage during the experiment with a
mean pathology and inflammatory cell infiltrate score of 0.08 and
0.08, respectively (Fig. 3A, 3B). At day 3 post exposure to SEB,
no significant difference was observed in mean lung pathology
scores or lung-to-body ratio for abatacept-treated mice compared
with SEB-control mice (0.4 versus 1.9, p . 0.05, Fig. 3A, and
1.317 versus 1.460, p . 0.05, Fig. 3C, respectively). However, a
significant decrease in inflammatory cell infiltrate was observed
between abatacept-treated mice and SEB-control mice (2.3 versus
3.9, respectively, p , 0.05; Fig. 3B). At day 6, a significant dif-
ference in abatacept-treated mice compared with SEB-treated
mice was observed for lung pathology scores (0.1 versus 3.6,
p , 0.001; Fig. 3A), lung inflammatory cell infiltrate (1.1 versus
2.6, p , 0.05; Fig. 3B), and lung-to-body ratio (0.864 versus
1.669, p , 0.01; Fig. 3C). Thus, abatacept treatment reduced lung
pathology from day 3 to day 6. This finding was supported by
representative H&E staining of lung tissue at day 6 (Fig. 4A–F).
No tissue damage or inflammatory infiltration was observed in
PBS-exposed mice, whereas SEB-exposed mice showed gran-
ulocyte infiltration into the lung with constriction and infiltration
of the alveolar sacs with WBCs (Fig. 4D, 4E). In contrast, SEB-
exposed mice treated with abatacept had no obvious WBC infil-
tration or tissue damage (Fig. 4F). We further evaluated the lungs
for edema by MRI of the lungs. PBS-treated mice showed no signs
of edema by MRI. SEB mice had visible fluid buildup in the lungs
at day 6, whereas abatacept-treated and PBS-control mice did not
have any observable fluid in the lungs (Fig. 4G–I, Supplemental
Fig. 4).
Abatacept treatment of SEB-exposed mice reduces local and
systemic release of proinflammatory cytokines and chemokines
To determine the ability of abatacept to reduce SEB-induced in-
flammation, we measured plasma cytokine and chemokine levels at
3, 6, and 14 d using Luminex assays. At day 3, several proin-
flammatory cytokines and chemokines were significantly raised in
either plasma and/or lung tissue compared with mice receiving PBS
FIGURE 1. Murine splenocyte prolif-
eration and cytokine assay. Isolated
splenocytes were treated with PBS (nega-
tive control), SEB (positive control), or
SEB and abatacept (n = 5). Proliferation
assays were performed. Abatacept-treated
cells were normalized against the negative
control and the positive SEB control (A)
(0 and 100%, respectively). Supernatants
were analyzed for IL-1b (B), IL-2 (C), and
CCL2 (D) production. Repeated-measures
ANOVA showed that the effect of treat-
ment was significant for proliferation, F(6,
24) = 7.141, p = 0.0002; IL-1b, F(6, 24) =
3.948, p = 0.0069; IL-2, F(6, 24) = 5.831,
p = 0.0007; and CCL2, F(6, 24) = 3.988,
p = 0.0065. Means of five replicates and
SEM are represented. Post hoc analysis
using Dunnett multiple comparison are
indicated. *p , 0.05, **p , 0.01, ***p ,
0.001. ns, p . 0.05.
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i.n. Notably, CXCL1, IFN-g, IL-1b, IL-6, IL-5, CCL2, and TNF-a
were raised significantly (p, 0.05; Figs. 5, 6, Supplemental Fig. 2).
Treatment with abatacept after SEB exposure reduced plasma
levels of IFN-g, IL-1b, and IL-6 significantly compared with SEB
at day 3 (p , 0.001; Fig. 6). Furthermore, lung cytokine and
chemokine levels of CCL2, IFN-g, IL-5, and IL-6 were signifi-
cantly lower in the abatacept-treated group compared with the
SEB-exposed mice, indicating that abatacept therapy reduces in-
flammatory cytokine and chemokine levels at the site of SEB
exposure (p , 0.01 for all cytokines; Fig. 6, Supplemental Fig. 3).
Surprisingly, systemic levels of TNF-a remained elevated after
abatacept treatment compared with PBS-control mice (Fig. 5).
Furthermore, TNF-a was statistically higher in the treatment
group compared with the PBS-control group at 3 d post exposure
in plasma (p , 0.0001) and lung tissue (p , 0.001) (Figs. 5, 6),
thus indicating that effective therapeutic treatment of SEB is not
dependent upon the reduction in systemic levels of TNF-a at day 3
in this model. Although this result was surprising, it should be
noted that earlier time points were not investigated, and thus an
earlier systemic reduction of TNF-a may have been missed.
Furthermore, lung tissue levels of TNF-a were significantly re-
duced at day 3 in the abatacept-treated group compared with the
SEB-exposed mice (Fig. 6). IL-2 levels were also significantly
raised in the SEB-exposed mice compared with the PBS-control
mice (Fig. 5). In the treated group there was a trend in reduction of
IL-2, although this reduction did not reach significance (Fig. 5).
Abatacept treatment of SEB-exposed human PBMCs reduces
release of proinflammatory cytokines
The effects of SEB, abatacept, and CTLA4 antagonist ipilimumab
were tested in vitro on human PBMCs. Ipilimumab was used as a
positive control and also to sensitize human PBMCs to the effects
of SEB. After treatments, IFN-g, IL-2, and TNF-a levels were
quantified by flow cytometry and ELISA; median baseline values
of unstimulated PBMCs were 2.19, 1.00, and 1.04 pg/ml, re-
spectively. No significant changes in intracellular cytokine levels
were observed among the three treatment groups (Fig. 7B).
However, when PBMCs exposed to SEB were treated with ipili-
mumab at 10 mg/ml, levels of TNF-a and IL-2 in the culture
medium were significantly raised compared with cells exposed to
SEB only (median values 6200 versus 4100 and 4400 versus 3300
pg/ml, respectively, for TNF-a and IL-2; p , 0.0001; Fig. 7C).
IL-2 production in cultured human PBMCs exposed to SEB was
significantly reduced by abatacept treatment when compared with
controls (median values 3300 versus 1900 pg/ml, respectively;
p , 0.0001).
FIGURE 2. Murine model of SEB with abatacept treatment. Kaplan–Meier plot of SEB mouse survival exposed to 0.25 and 0.5 mg SEB per gram of
mouse weight (A) and weight change after abatacept treatment at 3 (B) or 8 h (C) postexposure. Significant differences in survival were observed between
the control PBS group and mice receiving 0.5 mg/g SEB (x2 = 24.24, p , 0.0001) or 0.25 mg/g SEB (x2 = 5.52, p = 0.0188). For weight change, graphs
represent mean with error bars for 95% CI. Clinical signs of mice receiving PBS (D), SEB (E), or SEB followed by abatacept treatment (F) at 8 h are shown.
Graphs represent the percentage of mice with severe, moderate, mild, or no clinical signs plotted for each time point. Statistical differences are summarized
as: *p , 0.05, ****p , 0.0001.
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Our findings show that after an i.n. challenge with SEB, a single
dose of abatacept is effective at preventing morbidity and lung
injury in mice. Abatacept treatment also reduces the production of
the proinflammatory cytokines INF-g and IL-6, both systemically
and in lung tissue. The severity of pathology after SEB exposure
is heavily dependent upon the route of exposure. SEB is more
toxic via inhalation, compared with ingestion, and severe lung
damage after exposure to SEB aerosols has been demonstrated
(23). Numerous animal models of SEB intoxication have been
developed that use survival as a primary outcome for the efficacy
of medical countermeasures (24, 25). However, weaponized SEB
has potential incapacitating properties for exposed military
personnel because of the ED50 (the median effective dose of
incapacitation) being ∼50 times lower than the LD50 (26, 27).
We therefore chose to develop a sublethal model of i.n. SEB
FIGURE 4. Histopathology and MRI of lungs after SEB intoxication in mice. Tissue sections were stained using H&E, at a nominal 5-mm
thickness before assessment [SEB treated (A, D, and E); PBS-control (B); and SEB after abatacept therapy (C and F)]. White boxes highlight air
space within the lung, and white arrows indicate inflammatory cell infiltrate; SEB lung pathology is predominantly characterized by an acute
alveolar inflammatory cell infiltrate. Scale bar, 100 mm. Mice were sacrificed on days 3, and whole-body imagery was performed on SEB-treated
(G), PBS-control (H), or SEB mice treated with abatacept at 8 h (I). White boxes indicate lung cavity, whereas gray shading within white boxes
indicates the presence of fluid.
FIGURE 3. Lung pathology scores and organ to body percent weight of lung. Lungs were removed and scored for visible signs of damage (A) and
histopathology scores (B), and subsequently weighed to determine the lung-to-body weight ratio (C). Scores ranged from 1 (normal) to 4 (very severe lung
pathology/75–100% inflammatory cell infiltrate), as defined in the Materials and Methods. Lung visual pathology, cell infiltrate scores, and lung-to-body
weight ratio were analyzed by Kruskal–Wallis test with post hoc Dunn multiple comparison test. Visual pathology scores significance for treatment were:
day 3, p = 0.0002; day 6, p , 0.0001; and day 14, p = 0.0169. Cell infiltrate scores significance for treatment were: day 3, p , 0.0001; day 6, p , 0.0001;
and day 14, p = 0.0029. Lung-to-body weight ratio had significant differences in treatment: day 3, p , 0.0001; day 6, p , 0.0001; and day 14, p = 0.0059.
Graphs for lung pathology, histopathology scores, and lung-to-body weight ratio represent median and range. Post hoc analysis using Dunnett multiple
comparison are indicated. *p , 0.05, **p , 0.01, ***p , 0.001. ns, p . 0.05.
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administration. The current murine model for SEB intoxication
was optimized to maximize severity, but with minimal lethality:
SEB exposure induced weight loss close to the 30% limit, at which
animals are required to be sacrificed. Although our murine model
does not measure the most extreme scenario of SEB exposure
leading to mortality, it does reflect the most likely level of disease
that would occur in the majority of exposed humans. Another
advantage of our murine model is that no additional sensitizing
agent is required in conjunction with SEB exposure. Other murine
models require potentiating agents such as LPS, actinomycin D, or
D-galactosamine to be given in conjunction with SEB because
mice are less sensitive to SEB than humans (13, 23). These po-
tentiating agents may mask the efficacy of otherwise effective
medical countermeasures (28). D-Galactosamine has been shown
to cause liver damage, and LPS is known to induce inflammatory
pathways through TLR4 rather than through the APC/T cell im-
munological synapse, as occurs after exposure of SEB (29, 30).
When investigating novel medical countermeasures that work by
modulating the host response to SEB, either a previously pub-
lished model utilizing a humanized MHC class II or a model that
uses a high dose of SEB given i.n. is preferred. Safety consider-
ations limit the use of such high concentrations of SEB. Therefore,
we chose to develop a challenge model with a dose of SEB leading
to a primary end point of severe (30%) weight loss. It should be
noted that the rate of SEB absorption via i.n. administration
compared with aerosolized exposures is likely to be slower. Ad-
ditional survival studies in nonhuman primates using previously
characterized aerosolization models is required to further deter-
mine abatacept efficacy for treatment after SEB exposure (31).
Our findings demonstrate that SEB-dependent morbidity was
significantly reduced by the administration of a single dose of
abatacept at 8 h post SEB exposure. Previous studies have
demonstrated that efficacious therapies for SEB exposure such as
lovastatin and SEB antitoxin increased survival of treated mice by
70% if both compounds were given in conjunction with SEB
rather than being administered postexposure (32). Prophylactic
treatment of mice with abatacept reduced mortality after expo-
sure to the superantigen toxic shock syndrome toxin (TSST) by
75% (33). Treatment of SEB exposure by dexamethasone and
rapamycin also reduced mortality (10, 34). However, rapamycin
and dexamethasone treatment was given 5 h after exposure and
required additional administration at 24 h timepoints for 4 d after
intoxication.
By contrast, our study showed that a medical countermeasure
is available that can be given as a single dose administered up to
8 h after SEB exposure. SEB exposure in vivo resulted in sig-
nificant increases in proinflammatory cytokines IL-5, IFN-g, and
IL-6 in plasma and lungs. We show that abatacept treatment
significantly reduced the levels of these cytokines that are in-
dicators of systemic inflammation, which regulates T cell re-
sponses and the proinflammatory response of eosinophils (35,
36). Pathology induced by SEB is dependent upon T cell and
eosinophil activation, and subsequently will lead to a systemic
inflammatory response (37). We also observed that SEB-
dependent IL-2 expression in human and murine cell cultures
was prevented by abatacept. However, this phenomenon was not
observed in vivo. The canonical role of IL-2 is to promote T cell
expansion (38, 39). This suggests that IL-2 induction in vivo by
FIGURE 5. Plasma concentrations
of cytokines. Plasma concentrations
of IFN-g (A), IL-6 (B), IL-1b (C), IL-
5 (D), TNF-a (E), and IL-2 (F) were
measured for six animals in the SEB
negative control, PBS positive con-
trol, and SEB-treated groups at 3, 6,
and 14 d post SEB exposure. Two-
way ANOVA analysis was performed
for cytokines with post hoc Bonfer-
roni multiple comparison test. Signi-
ficance for treatment was: IFN-g,
F(2, 46) = 34.75, p , 0.0001; IL-6, F
(2, 46) = 9.61, p = 0.0003; IL-1b, F
(2, 46) = 3.88, p = 0.0277; IL-5, F(2,
46) = 1.87, p = 0.1652; TNF-a, F
(2, 46) = 346.15, p, 0.0001; and IL-
2, F(2, 46) = 7.66, p = 0.0013.
Significance for time was: IFN-g, F
(2, 46) = 44.37, p , 0.0001; IL-6,
F(2, 46) = 22.23, p , 0.0001; IL-1b,
F(2, 46) = 5.19, p = 0.0093; IL-5, F
(2, 46) = 5.32, p = 0.0084; TNF-a, F
(2, 46) = 8.28, p = 0.0008; and IL-2,
F(2, 46) = 1.41, p = 0.254. Graphs
depict mean cytokine values with SEM.
Post hoc Bonferroni multiple comparison
tests are summarized as: *p , 0.05,
**p , 0.01, ****p , 0.0001.
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SEB has peaked before day 3, and indeed Krakauer et al. (28)
demonstrated a significant increase in IL-2 expression up to 24 h
post exposure, and this may have been missed in sera collected
on day 3. Previous studies have demonstrated that IL-1b is
predominately produced by monocytes after superantigen ex-
posure (40). Reduction of IL-1b levels after abatacept treatment
both in vitro and in vivo indicates the drug also reduces APC
activation. TNF-a levels were significantly reduced by abata-
cept in murine PBMCs in vitro; however, murine plasma levels
of TNF-a remained high at days 3, 6, and 14 after SEB expo-
sure, and these were not affected by abatacept treatment. In
human PBMCs, abatacept did not significantly reduce TNF-a
production in vitro, whereas ipilimumab, an activator of the
immune response and an antagonist of CTLA4, did significantly
increase TNF-a production. Thus, modifications of the immune
synapse can affect TNF-a secretion levels. Our findings show
that weight loss and clinical signs remain unaffected in SEB-
treated mice after abatacept therapy. We have demonstrated
changes in TNF-a in our studies. However, mice treated with
abatacept do not show reduced systemic TNF-a. Importantly,
this study indicates that plasma TNF-a levels are not an ap-
propriate biomarker for determining murine responses with
abatacept treatment. Furthermore, it implies that TNF-a may
not play a critical role in the clinical outcomes in subjects ex-
posed to sublethal levels of superantigens, at least when B7
receptor antagonists are used (38). However, at lethal levels of
superantigen exposure, TNF-a antagonist may have utility as a
combined therapeutic. It should also be noted that the immu-
nological response to SEB was less obvious in human PBMCs to
the murine splenocyte assay and in in vivo studies. Although
this difference may be because of species-specific responses, the
observed differences were likely because of the cellular com-
position of the two in vitro models and mouse model used in our
study. Although others have found that TNF-a expression is
critical to SEB immunopathology (28), our observations suggest
that IFN-g and IL-6 in plasma samples may be better bio-
markers for monitoring patient responses with abatacept treat-
ment. This approach should be confirmed in humans.
Abatacept is a commercially licensed drug for the treatment of
rheumatoid arthritis and is considered safe (41). The therapeutic
doses of abatacept used in our studies are within tolerable dose
ranges for rheumatoid arthritis treatment in humans. Abatacept
prevents T cell activation by blocking the B7/CD28 receptors,
which is preventing the costimulatory signal in the presence of
superantigens such as SEB (42). Thus, abatacept may prevent
pathology from a broad range of superantigens; for example,
abatacept has been previously shown to prevent TSST-dependent
mortality in mice (33). In addition to preventing SEB and TSST
pathology, it is likely that abatacept will have efficacy at pre-
venting other superantigen-related disease. Indeed, other super-
antigens produced by S. aureus, such as staphylococcal
enterotoxins A to G, stimulate T cells and release inflammatory
cytokines similar to the cytokine storm observed after SEB ex-
posure (42). This suggests a utility of abatacept to treat SEB ef-
fectively, as well as provide a broad range of efficacy to other
staphylococcal enterotoxins and TSST-1. Furthermore, recent re-
search has indicated that superantigens selectively anergize T cells
to protect the pathogen from the host immune response (43). Thus,
abatacept and therapeutic agents targeting the costimulatory
pathway may be able to aid treatment of a broad range of bacterial
and viral infections.
In conclusion, we have demonstrated that abatacept prevents
severe pathology caused by SEB exposure in a murine model, and
that a single dose of abatacept given i.v. up to 8 h postexposure is
effective. Abatacept prevents lung damage and reduces local and
systemic inflammation. The reduction of IL-6 and IFN-g levels is
indicative of the host response to therapy and a potential correlate
of protection against SEB intoxication. Further studies on new
FIGURE 6. Lung tissue extract concentrations of IFN-g, IL-6, CCL2, IL-1b, IL-5, and TNF-a. Lung tissue extract concentrations of IFN-g (A),
IL-6 (B), CCL2 (C), IL-1b (D), IL-5 (E), and TNF-a (F) were measured. One-way ANOVA analysis was performed for cytokines with post hoc
Dunnett multiple comparison test. Significance for treatment was: IFN-g, F(2, 15) = 10.04, p = 0.0017; IL-6, F(2, 15) = 14.95, p = 0.0003; CCL2,
F(2, 15) = 13.16, p = 0.0005; IL-1b, F(2, 15) = 3.729, p = 0.0485; IL-5, F(2, 15) = 6.120, p = 0.0114; and TNF-a, F(2, 15) = 10.29, p = 0.0015.
Significant difference graphs depict mean cytokine values with SEM. Post hoc Dunnett multiple comparison test are summarized as: *p , 0.05, **p ,
0.01, ***p , 0.001.
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compounds that bind to the B7 receptor, such as the CD28 mi-
metic AB103, would be of interest (44). Further research is needed
using nonhuman primate lethal and sublethal aerosolized exposure
models to demonstrate the efficacy of abatacept, to prevent pa-
thology from superantigen exposure.
Acknowledgments
We thank Stuart Armstrong, Jan Platt, Phillippa Payne, Vicky Cox, and
Louise Thompsett for technical and personal support of this project at
the Defence Science and Technology Laboratory. We thank Stephanie
Nygard and Joey Mosqueda at Washington University for support in editing
the manuscript.
Disclosures
The authors have no financial conflicts of interest.
References
1. Ulrich, R. G., S. Sidell, T. J. Taylor, C. L. Wilhelmsen, and D. R. Franz. 1997.
Staphylococcal enterotoxin B and related pyrogenic toxins. In Medical As-
pects of Chemical and Biological Warfare. R. Zajchuk, and R. F. Bellamy, eds.
Office of the Surgeon General, US Department of the Army, Washington, DC,
p. 621–630.
2. Lindsay, C. D., and G. D. Griffiths. 2013. Addressing bioterrorism concerns:
options for investigating the mechanism of action of Staphylococcus aureus
enterotoxin B. Hum. Exp. Toxicol. 32: 606–619.
3. Fraser, J. D. 2011. Clarifying the mechanism of superantigen toxicity. PLoS Biol.
9: e1001145.
4. Kashiwada, T., K. Kikuchi, S. Abe, H. Kato, H. Hayashi, T. Morimoto,
K. Kamio, J. Usuki, S. Takeda, K. Tanaka, et al. 2012. Staphylococcal en-
terotoxin B toxic shock syndrome induced by community-acquired
methicillin-resistant Staphylococcus aureus (CA-MRSA). Intern. Med. 51:
3085–3088.
5. Kumar, S., A. Me´noret, S.-M. Ngoi, and A. T. Vella. 2010. The systemic and
pulmonary immune response to staphylococcal enterotoxins. Toxins (Basel) 2:
1898–1912.
6. Shinbori, T., M. Matsuki, M. Suga, K. Kakimoto, and M. Ando. 1996. Induction
of interstitial pneumonia in autoimmune mice by intratracheal administration of
superantigen staphylococcal enterotoxin B. Cell. Immunol. 174: 129–137.
7. Strandberg, K. L., J. H. Rotschafer, S. M. Vetter, R. A. Buonpane, D. M. Kranz,
and P. M. Schlievert. 2010. Staphylococcal superantigens cause lethal pulmonary
disease in rabbits. J. Infect. Dis. 202: 1690–1697.
8. Tilahun, M. E., G. Rajagopalan, N. Shah-Mahoney, R. G. Lawlor, A. Y. Tilahun,
C. Xie, K. Natarajan, D. H. Margulies, D. I. Ratner, B. A. Osborne, and
R. A. Goldsby. 2010. Potent neutralization of staphylococcal enterotoxin B by
synergistic action of chimeric antibodies. Infect. Immun. 78: 2801–2811.
9. Krakauer, T., M. J. Buckley, L. M. Huzella, and D. A. Alves. 2009. Critical
timing, location and duration of glucocorticoid administration rescue mice from
superantigen-induced shock and attenuate lung injury. Int. Immunopharmacol. 9:
1168–1174.
10. Krakauer, T., and M. Buckley. 2006. Dexamethasone attenuates staphylococcal
enterotoxin B-induced hypothermic response and protects mice from
superantigen-induced toxic shock. Antimicrob. Agents Chemother. 50: 391–395.
11. Krakauer, T. 2013. Update on staphylococcal superantigen-induced signaling
pathways and therapeutic interventions. Toxins (Basel) 5: 1629–1654.
12. Kaempfer, R., G. Arad, R. Levy, D. Hillman, I. Nasie, and Z. Rotfogel. 2013.
CD28: direct and critical receptor for superantigen toxins. Toxins (Basel) 5:
1531–1542.
13. LeClaire, R. D., R. E. Hunt, S. Bavari, J. E. Estep, G. O. Nelson, and
C. L. Wilhelmsen. 1996. Potentiation of inhaled staphylococcal enterotoxin
B-induced toxicity by lipopolysaccharide in mice. Toxicol. Pathol. 24: 619–626.
14. Arad, G., R. Levy, I. Nasie, D. Hillman, Z. Rotfogel, U. Barash, E. Supper,
T. Shpilka, A. Minis, and R. Kaempfer. 2011. Binding of superantigen toxins
into the CD28 homodimer interface is essential for induction of cytokine genes
that mediate lethal shock. [Published erratum appears in 2015 PLoS Biol. 13:
e1002237.] PLoS Biol. 9: e1001149.
15. Krakauer, T. 2010. Therapeutic down-modulators of staphylococcal
superantigen-induced inflammation and toxic shock. Toxins (Basel) 2: 1963–
1983.
16. Qureshi, O. S., Y. Zheng, K. Nakamura, K. Attridge, C. Manzotti, E. M. Schmidt,
J. Baker, L. E. Jeffery, S. Kaur, Z. Briggs, et al. 2011. Trans-endocytosis of CD80
and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science
332: 600–603.
17. Hoff, H., P. Kolar, A. Ambach, A. Radbruch, and M. C. Brunner-Weinzierl.
2010. CTLA-4 (CD152) inhibits T cell function by activating the ubiquitin ligase
Itch. Mol. Immunol. 47: 1875–1881.
18. Moreland, L., G. Bate, and P. Kirkpatrick. 2006. Abatacept. Nat. Rev. Drug
Discov. 5: 185–186.
19. Knoerzer, D. B., R. W. Karr, B. D. Schwartz, and L. J. Mengle-Gaw. 1995.
Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with
CTLA-4-Ig. J. Clin. Invest. 96: 987–993.
20. McKallip, R. J., H. F. Hagele, and O. N. Uchakina. 2013. Treatment with the
hyaluronic acid synthesis inhibitor 4-methylumbelliferone suppresses SEB-
induced lung inflammation. Toxins (Basel) 5: 1814–1826.
FIGURE 7. Human PBMC stimulation assay for intracellular and secreted cytokine expression. Human PBMCs isolated from volunteers and treated with
SEB in combination with PBS (control), abatacept (1 and 10 mg/ml of treatment), or ipilimumab (1 and 10 mg/ml of CTLA4 pathway antagonist). In-
tracellular cytokine production was determined by flow cytometry for TNF-a, IL-2, and IFN-g (n = 3 per group). Representative gating strategy (A) and
pooled data are shown (B). Supernatants were analyzed by ELISA to determine secretion TNF-a, IL-2, and IFN-g (n = 4 per group) (C). Two-way ANOVA
with Dunnett multiple comparison test. Significance for intracellular cytokine treatment was F(2, 6) = 3.25, p = 0.6805 and for ELISAwas F(2, 9) = 14.31,
p = 0.0016. Bar graphs represent median 95% CI. Post hoc Dunnett multiple comparison test are summarized as: *p , 0.05, ****p , 0.0001.
The Journal of Immunology 3997










21. Pala, P., T. Hussell, and P. J. Openshaw. 2000. Flow cytometric measurement of
intracellular cytokines. J. Immunol. Methods 243: 107–124.
22. Chen, J. Y., Y. Qiao, J. L. Komisar, W. B. Baze, I. C. Hsu, and J. Tseng. 1994.
Increased susceptibility to staphylococcal enterotoxin B intoxication in mice
primed with actinomycin D. Infect. Immun. 62: 4626–4631.
23. Huvenne, W., E. A. Lanckacker, O. Krysko, K. R. Bracke, T. Demoor,
P. W. Hellings, G. G. Brusselle, G. F. Joos, C. Bachert, and T. Maes. 2011.
Exacerbation of cigarette smoke-induced pulmonary inflammation by Staphy-
lococcus aureus enterotoxin B in mice. Respir. Res. 12: 69.
24. Roy, C. J., K. L. Warfield, B. C. Welcher, R. F. Gonzales, T. Larsen, J. Hanson,
C. S. David, T. Krakauer, and S. Bavari. 2005. Human leukocyte antigen-DQ8
transgenic mice: a model to examine the toxicity of aerosolized staphylococcal
enterotoxin B. Infect. Immun. 73: 2452–2460.
25. Savransky, V., V. Rostapshov, D. Pinelis, Y. Polotsky, S. Korolev, J. Komisar, and
K. Fegeding. 2003. Murine lethal toxic shock caused by intranasal administra-
tion of staphylococcal enterotoxin B. Toxicol. Pathol. 31: 373–378.
26. Franz, D. R. 1997. Defence against Toxic Weapons. US Army Medical Research
Materiel Command. US Department of the Army, Fort Detrick, MD, p. 1–60.
27. Pinchuk, I. V., E. J. Beswick, and V. E. Reyes. 2010. Staphylococcal entero-
toxins. Toxins (Basel) 2: 2177–2197.
28. Krakauer, T., M. J. Buckley, and D. Fisher. 2010. Proinflammatory mediators
of toxic shock and their correlation to lethality. Mediators Inflamm. 2010:
517594.
29. Yin, T., S. Q. Tong, Y. C. Xie, and D. Y. Lu. 1999. Cyclosporin A protects Balb/c
mice from liver damage induced by superan tigen SEB and D-GalN. World J.
Gastroenterol. 5: 209–212.
30. Beno, D. W., M. R. Uhing, M. Goto, Y. Chen, V. A. Jiyamapa-Serna, and
R. E. Kimura. 2001. Staphylococcal enterotoxin B potentiates LPS-induced
hepatic dysfunction in chronically catheterized rats. Am. J. Physiol. Gastro-
intest. Liver Physiol. 280: G866–G872.
31. Hartings, J. M., and C. J. Roy. 2004. The automated bioaerosol exposure system:
preclinical platform development and a respiratory dosimetry application with
nonhuman primates. J. Pharmacol. Toxicol. Methods 49: 39–55.
32. Tilahun, M. E., A. Kwan, K. Natarajan, M. Quinn, A. Y. Tilahun, C. Xie,
D. H. Margulies, B. A. Osborne, R. A. Goldsby, and G. Rajagopalan. 2011.
Chimeric anti-staphylococcal enterotoxin B antibodies and lovastatin act syn-
ergistically to provide in vivo protection against lethal doses of SEB. PLoS One
6: e27203.
33. Saha, B., B. Jaklic, D. M. Harlan, G. S. Gray, C. H. June, and R. Abe. 1996.
Toxic shock syndrome toxin-1-induced death is prevented by CTLA4Ig. J.
Immunol. 157: 3869–3875.
34. Krakauer, T., M. Buckley, H. J. Issaq, and S. D. Fox. 2010. Rapamycin protects
mice from staphylococcal enterotoxin B-induced toxic shock and blocks cyto-
kine release in vitro and in vivo. Antimicrob. Agents Chemother. 54: 1125–1131.
35. Taylor, A., J. Verhagen, K. Blaser, M. Akdis, and C. A. Akdis. 2006. Mecha-
nisms of immune suppression by interleukin-10 and transforming growth factor-
beta: the role of T regulatory cells. Immunology 117: 433–442.
36. Daser, A., N. Meissner, U. Herz, and H. Renz. 1995. Role and modulation of
T-cell cytokines in allergy. Curr. Opin. Immunol. 7: 762–770.
37. Liu, L. Y., S. K. Mathur, J. B. Sedgwick, N. N. Jarjour, W. W. Busse, and E. A.
B. Kelly. 2006. Human airway and peripheral blood eosinophils enhance Th1
and Th2 cytokine secretion. Allergy 61: 589–597.
38. Smith, K. A. 1988. Interleukin-2: inception, impact, and implications. Science
240: 1169–1176.
39. Khan, A. A., S. Priya, and B. Saha. 2009. IL-2 regulates SEB induced toxic
shock syndrome in BALB/c mice. PLoS One 4: e8473.
40. Szabo, G., P. Mandrekar, and D. Catalano. 1995. Inhibition of superantigen-
induced T cell proliferation and monocyte IL-1 b, TNF-a, and IL-6 produc-
tion by acute ethanol treatment. J. Leukoc. Biol. 58: 342–350.
41. Buch, M. H., E. M. Vital, and P. Emery. 2008. Abatacept in the treatment of
rheumatoid arthritis. Arthritis Res. Ther. 10(Suppl. 1): S5.
42. Dauwalder, O., D. Thomas, T. Ferry, A. L. Debard, C. Badiou, F. Vandenesch,
J. Etienne, G. Lina, and G. Monneret. 2006. Comparative inflammatory prop-
erties of staphylococcal superantigenic enterotoxins SEA and SEG: implications
for septic shock. J. Leukoc. Biol. 80: 753–758.
43. Sa¨hr, A., S. Fo¨rmer, D. Hildebrand, and K. Heeg. 2015. T-cell activation or tol-
erization: the Yin and Yang of bacterial superantigens. Front. Microbiol. 6: 1153.
44. Bulger, E. M., R. V. Maier, J. Sperry, M. Joshi, S. Henry, F. A. Moore,
L. L. Moldawer, D. Demetriades, P. Talving, M. Schreiber, et al. 2014. A novel
drug for treatment of necrotizing soft-tissue infections: a randomized clinical
trial. JAMA Surg. 149: 528–536.
3998 ABATACEPT PREVENTS STAPHYLOCOCCAL ENTEROTOXIN B PATHOLOGY










Supplementary Figure  1 
Supplementary Figure 1.  Murine splenoctye cytotoxicity assay.  Isolated splenocytes were treated with PBS (negative 
control), SEB (positive control) or with SEB and abatacept. After 24hr cell cytotoxicity assays were performed.  The ability of 
abatacept to inhibit the cytotoxic effect of SEB was investigated using a Promega MultiTox-Flour Multiplex Cytotoxicity 
Assay according to the manufacturer’s instructions (Promega, USA). Cell toxicity assays were performed on 4 separate 
occasions using splenocytes only; splenocytes treated with abatacept; splenocytes exposed to SEB and splenocytes exposed 
to SEB and treated with abatacept.  Dead cell numbers were determined using fluorescence at 485Ex / 535Em 3hr after 
addition of the 5x MultiFlour 5 reagent prepared according to the manufacturers guidance.  Repeated measures ANOVA 
showed that the effect of treatment was significant for proliferation F(3, 9)=4.989, p=0.0262. Means of 5 replicates and 
SEM are represented Post hoc analysis using Dunnett’s multiple comparison are indicated ns = p>0.05; * = p<0.05; ** = 
p<0.01; *** = p<0.001; **** = p<0.0001. 
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Supplemental Figure 2 


































































































Supplemental Figure 2. Plasma concentrations of CXCL1, CXCL2, IL-17A, CCL2, IL-12p70, IL-4, GM-CSF, VEGF and IL-10. Plasma concentrations CXCL1, 
CXCL2, IL-17A, CCL2, IL-12p70, IL-4, GM-CSF, VEGF and IL-10 (A to I respectively) were measured for 6 animals in the SEB negative control group, PBS 
positive control and SEB treated groups at day 3 days post SEB exposure. Two-way ANOVA analysis was performed for cytokines with post hoc 
Bonferroni multiple comparison test. Significance for treatment was CXCL1 F(2, 46)=1.60, p=0.2134; CXCL2 F(2, 46)=65.15, p<0.0001; IL-17A F(2, 
46)=6.47, p=0.0033;  CCL2 F(2, 46)=6.85, p=0.0025; IL-12p70 F(2, 46)=2.62, p=0.0839 IL-4 F(2, 46)=1.48, p=0.2383; GM-CSF F(2, 46)=9.05, p=0.0005; 
VEGF F(2, 46)=0.5, p=0.5645 and IL-10 F(2, 46)=3.32, p=0.0451. Significance for time was CXCL1 F(2, 46)=2.98, p=0.0608; CXCL2 F(2, 46)=0.29, 
p=0.7460; IL-17A F(2, 46)=2.97, p=0.0613; CCL2 F(2, 46)=3.75, p=0.0309; IL-17p70 F(2, 46)=2.07, p=0.1375; IL-4 F(2, 46)=1.62, p=0.209; GM-CSF F(2, 
46)=0.88, p=0.4204; VEGF F(2, 46)=2.05, p=0.1403 and IL-10 F(2, 46)=2.59, p=0.0858. Graphs depict mean cytokine values with SEM. Post hoc 













































































































































































































Supplemental Figure 3 





Supplemental Figure 3. Lung tissue extract concentrations of CXCL1, CCXL2, IL-17A, Il-12p70, IL-2, IL-4, IL-10, GMCSF and VEGF. Lung tissue extract 
concentrations CXCL1, CXCL2, IL-17A, IL-12p70, IL-2, IL4, IL-10, GM-CSF and VEGF (A to I respectively) were measured for 6 animals in the SEB negative 
control group, PBS positive control and SEB treated groups at day 3 days post SEB exposure. One-way ANOVA analysis was performed for cytokines with 
post hoc Dunnett’s multiple comparison test. Significance for treatment was CXCL1 F(2, 15)=0.7569, p=0.4862; IL-17A F(2, 15)=1.33, p=0.2932; IL-12p70 
F(2, 15)=1.180, p=0.3342; IL-4 F(2, 15)=4.259, p=0.0343; IL-10 F(2, 15)=8.632, p=0.0032; GM-CSF F(2, 15)=0.7689, p=0.4809 and VEGF F(2, 15)=0.8173, 
p=0.4603. Graphs depict mean cytokine values with SEM. Post hoc Dunnett’s multiple comparison test are summarised as ns = p>0.05; * = p<0.05; ** = 
p<0.01; *** = p<0.001; **** = p<0.0001 
 
Supplemental Figure 4 
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Supplementary Figure Supplemental Figure 4. Magnetic Resonance Imaging of lungs following SEB intoxication in mice.  
Groups of mice (3 per group) were dosed with SEB i.n. and PBS intravenously (A and D), PBS i.n. and PBS intravenously 
(Figure B and E) or SEB i.n. and abatacept (10mg/Kg mouse) (C and F). Intravenous PBS or abatacept was administered 8hr 
post SEB i.n. challenge. Mice were sacrificed on days 3 whole body imagery was performed.  Representative MRI scans for 
each group in the study are shown (A, B & C), where white boxes indicate the lung cavity and grey shading indicates fluid 
accumulation in the lungs.  
 
